Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional Results available

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

ClinicalTrials.gov ID: NCT02888743

Public ClinicalTrials.gov record NCT02888743. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This randomized phase II trial studies the side effects of durvalumab and tremelimumab and to see how well they work with or without high or low-dose radiation therapy in treating patients with colorectal or non-small cell lung cancer that has spread to other parts of the body (metastatic). Immunotherapy with durvalumab and tremelimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving durvalumab and tremelimumab with radiation therapy may work better in treating patients with colorectal or non-small cell lung cancer.

Study identification

NCT ID
NCT02888743
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Enrollment
110 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 14, 2017 (Actual)
Primary completion
Dec 31, 2023 (Actual)
Completion
Jan 2, 2027 (Estimated)
Last update posted
Jul 31, 2026

2017 – 2027

United States locations

U.S. sites
41
U.S. states
18
U.S. cities
32
Facility City State ZIP Site status
Mayo Clinic Hospital in Arizona Phoenix Arizona 85054 —
Mayo Clinic in Arizona Scottsdale Arizona 85259 —
Los Angeles General Medical Center Los Angeles California 90033 —
USC / Norris Comprehensive Cancer Center Los Angeles California 90033 —
University of California Davis Comprehensive Cancer Center Sacramento California 95817 —
Smilow Cancer Hospital Care Center - Guilford Guilford Connecticut 06437 —
Smilow Cancer Hospital Care Center at Saint Francis Hartford Connecticut 06105 —
Smilow Cancer Center/Yale-New Haven Hospital New Haven Connecticut 06510 —
Yale University New Haven Connecticut 06520 —
Yale-New Haven Hospital North Haven Medical Center North Haven Connecticut 06473 —
Smilow Cancer Hospital Care Center-Trumbull Trumbull Connecticut 06611 —
Smilow Cancer Hospital Care Center - Waterford Waterford Connecticut 06385 —
Mayo Clinic in Florida Jacksonville Florida 32224-9980 —
Emory University Hospital Midtown Atlanta Georgia 30308 —
Emory University Hospital/Winship Cancer Institute Atlanta Georgia 30322 —
Emory Saint Joseph's Hospital Atlanta Georgia 30342 —
University of Kentucky/Markey Cancer Center Lexington Kentucky 40536 —
University of Maryland/Greenebaum Cancer Center Baltimore Maryland 21201 —
Massachusetts General Hospital Cancer Center Boston Massachusetts 02114 —
Brigham and Women's Hospital Boston Massachusetts 02115 —
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 —
Dana-Farber Cancer Institute Boston Massachusetts 02215 —
Wayne State University/Karmanos Cancer Institute Detroit Michigan 48201 —
Weisberg Cancer Treatment Center Farmington Hills Michigan 48334 —
Mayo Clinic in Rochester Rochester Minnesota 55905 —
Siteman Cancer Center at Saint Peters Hospital City of Saint Peters Missouri 63376 —
Siteman Cancer Center at West County Hospital Creve Coeur Missouri 63141 —
Washington University School of Medicine St Louis Missouri 63110 —
Siteman Cancer Center-South County St Louis Missouri 63129 —
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital New Brunswick New Jersey 08903 —
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903 —
UNC Lineberger Comprehensive Cancer Center Chapel Hill North Carolina 27599 —
Duke University Medical Center Durham North Carolina 27710 —
Cleveland Clinic Foundation Cleveland Ohio 44195 —
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 —
Thomas Jefferson University Hospital Philadelphia Pennsylvania 19107 —
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15232 —
Vanderbilt University/Ingram Cancer Center Nashville Tennessee 37232 —
University of Virginia Cancer Center Charlottesville Virginia 22908 —
VCU Massey Comprehensive Cancer Center Richmond Virginia 23298 —
University of Wisconsin Carbone Cancer Center - University Hospital Madison Wisconsin 53792 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02888743, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 31, 2026 · Synced Nov 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02888743 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →